Search details
1.
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
Gastroenterol Hepatol
; 45(5): 342-349, 2022 May.
Article
in English, Spanish
| MEDLINE | ID: mdl-34129903
2.
Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals.
Liver Int
; 41(12): 2885-2891, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34392590
3.
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Dig Dis Sci
; 62(3): 784-793, 2017 03.
Article
in English
| MEDLINE | ID: mdl-28078526
4.
Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
PLoS One
; 13(6): e0199926, 2018.
Article
in English
| MEDLINE | ID: mdl-29940039
5.
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study / Costes directos no farmacológicos de una estrategia simplificada con glecaprevir/pibrentasvir durante 8 semanas en pacientes naïve, no cirróticos, con hepatitis C, implementada en la práctica clínica. Estudio Just SIMPLE
Gastroenterol. hepatol. (Ed. impr.)
; 45(5): 342-349, May. 2022. tab, graf
Article
in English
| IBECS (Spain) | ID: ibc-204300
6.
Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
PLoS One
; 12(9): e0184550, 2017.
Article
in English
| MEDLINE | ID: mdl-28898281
Results
1 -
6
de 6
1
Next >
>>